IP Library Granted Patent US 9,669,133
Granted Patent B2
US 9,669,133 · App. 14/833,404 · Granted Jun 6, 2017

Extracellular matrix encasement structures and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,669,133
App. No.
14/833,404
Filed
Aug 24, 2015
Granted
Jun 6, 2017
Kind
B2
Art Unit
1632
USPC
424/572
Abstract

A pouch structure formed from extracellular matrix (ECM) derived from small intestine submucosa (SIS) that includes an internal region configured to receive a medical device therein. The pouch structure is configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of the damaged biological tissue, and regeneration of tissue structures with site-specific structural and functional properties, when implanted in a subject.

Claims (9)

1. A bioremodelable encasement structure, comprising:

a sheet member comprising an extracellular matrix (ECM) composition,

said ECM composition comprising acellular ECM from a decellularized mammalian tissue source, said decellularized mammalian tissue source comprising small intestine submucosa (SIS),

said ECM composition further comprising an additional hemostatic agent selected from the group consisting of fibronectin and chitosan,

said sheet member being folded, wherein said sheet member forms a pouch structure comprising an internal region that is configured to receive a medical device therein,

said pouch structure, when implanted in a subject, being configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of said damaged biological tissue, and regeneration of tissue structures with site-specific structural and functional properties.

2. The encasement structure of claim 1 , wherein said ECM composition further comprises an additional biologically active agent.

3. The encasement structure of claim 2 , wherein said biologically active agent comprises a fibroblast growth factor (bFGF).

4. The encasement structure of claim 1 , wherein said medical device comprises a device selected from the group consisting of a pacemaker, defibrillator and ventricular assist device.